CA3093196A1 - Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases - Google Patents

Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases Download PDF

Info

Publication number
CA3093196A1
CA3093196A1 CA3093196A CA3093196A CA3093196A1 CA 3093196 A1 CA3093196 A1 CA 3093196A1 CA 3093196 A CA3093196 A CA 3093196A CA 3093196 A CA3093196 A CA 3093196A CA 3093196 A1 CA3093196 A1 CA 3093196A1
Authority
CA
Canada
Prior art keywords
compound
method comprises
pharmaceutically acceptable
treat
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3093196A
Other languages
English (en)
French (fr)
Inventor
William R. Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Europe GmbH
Original Assignee
Amgen Europe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Europe GmbH filed Critical Amgen Europe GmbH
Publication of CA3093196A1 publication Critical patent/CA3093196A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CA3093196A 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases Pending CA3093196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07
US62/639,650 2018-03-07
PCT/EP2019/055576 WO2019170750A1 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Publications (1)

Publication Number Publication Date
CA3093196A1 true CA3093196A1 (en) 2019-09-12

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3093196A Pending CA3093196A1 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Country Status (11)

Country Link
US (1) US11639332B2 (https=)
EP (1) EP3762365B1 (https=)
JP (1) JP7396991B2 (https=)
AR (1) AR114666A1 (https=)
AU (1) AU2019229583B2 (https=)
CA (1) CA3093196A1 (https=)
ES (1) ES2987705T3 (https=)
MA (1) MA52266A (https=)
MX (1) MX2020009288A (https=)
TW (1) TW202000646A (https=)
WO (1) WO2019170750A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JPWO2002001667A1 (ja) * 2000-06-29 2004-01-08 日本化薬株式会社 色素増感光電変換素子
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
CA2718601A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.

Also Published As

Publication number Publication date
AR114666A1 (es) 2020-09-30
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
EP3762365A1 (en) 2021-01-13
TW202000646A (zh) 2020-01-01
JP7396991B2 (ja) 2023-12-12
ES2987705T3 (es) 2024-11-15
AU2019229583B2 (en) 2024-06-13
JP2021517134A (ja) 2021-07-15
US20200392082A1 (en) 2020-12-17
US11639332B2 (en) 2023-05-02
WO2019170750A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
JP6391071B2 (ja) シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
CN109748881A (zh) 胱硫醚-γ-裂合酶(CSE)抑制剂
FI61479C (fi) Foerfarande foer framstaellning av spasmolytiska nya d,l-tyrosinderivat
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
BR112020010429A2 (pt) uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
AU2020344820A1 (en) Use of NMN for the prevention and/or treatment of pain, and corresponding compositions
JP2023512622A (ja) ニタゾキサニド及びその活性型であるチゾキサニドのＳＡＲＳ－ＣｏＶ－２感染症の治療への適用
CN101522692A (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
JP2009523149A (ja) ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
TWI735790B (zh) N-取代之甘胺酸化合物的鋰鹽及其用途
ES2307626T3 (es) Agente terapeutico o preventivo para enfermedades del sistema disgestivo que contiene un derivado de diaminotrifluorometilpiridina.
AU2019229583B2 (en) Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases
IL274431B1 (en) Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome
WO2023142729A1 (zh) 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途
ES2233493T3 (es) Agentes terapeuticos y/o profilacticos para trastornos del sistema nervioso.
BR112021001984A2 (pt) composto, combinação, composição farmacêutica, conjunto de partes, uso de composto, e, método para tratamento de uma doença resultante de inflamação patológica
ES2978226T3 (es) Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
CN117379423A (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
CN116196314B (zh) Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
BR112021001966A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença resultante de inflamação patológica
CN105497021A (zh) 胺类化合物治疗焦虑障碍的医药用途
CN119925347A (zh) 化合物Pladienolide B作为抗蓖麻毒素保护剂的医药用途
WO2024002112A1 (zh) 一种治疗猫冠状或杯状病毒感染的方法
JPH0769895A (ja) 炎症性腸疾患治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250117

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250722

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251204